WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 1450
[post_author] => 3
[post_date] => 2015-03-12 16:15:37
[post_date_gmt] => 2015-03-12 16:15:37
[post_content] => Symbiotic Health, Inc, a New York City based company and Center for Biotechnology client, was named "Best in Show" at the first of MABA's 1st Pitch Life Science events in 2015, Symbiotic Health has developed a capsule to help kill Clostridium difficile (Cdiff) infection which causes severe, debilitating diarrhea, is the most frequent hospital-acquired infection in the US and an immediate public health threat that requires urgent and immediate action (CDC). The company's pipeline includes a capsule microbiome therapeutic designed to cure Cdiff by restoring a community of protective bacteria.
Dr. Gerard Honig, CEO of Symbiotic Health, presented on behalf of the company. Stephen M. Goodman, Co-founder of Mid Atlantic Bio Angels and a partner at Pryor Cashman LLP in New York City, also a panelist at the event said Dr. Honig's pitch and responses to questions demonstrated both mastery of the competitive space and a willingness to address challenges to his analysis calmly and directly. His style, as well as his substance, exemplified the maxim that it's not just the business plan but the management that ultimately brings a company success. Read more about the company and the competition here.
[post_title] => Symbiotic Health Wins Best in Show at 1st Pitch Competition
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => symbiotic-health-wins-best-in-show-at-1st-pitch-competition
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-02 17:58:26
[post_modified_gmt] => 2016-03-02 17:58:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1450
[menu_order] => 211
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3908
[post_author] => 1
[post_date] => 2022-06-13 13:15:29
[post_date_gmt] => 2022-06-13 13:15:29
[post_content] =>
The Center for Biotechnology will be co hosting a series of 6- 90 minute panel discussions with industry and government partners, focused on providing guidance and insight into how innovators can take their solution from the benchtop to the Biomedical Advanced Research & Development Authority (BARDA).
Each event will have its own specific focus, while contributing to a sequential flow for the series. Experts with specific backgrounds will provide an overview of key resources available to innovators to help fund and advance their solution from early through late stages of development, as well as provide guidance on how to navigate the funding opportunities within BARDA and BARDA DRIVe.
Session dates: June 14, 17, 21, 24, 28 and July 1st. 12:00om - 1:#0pm EST. Learn more and register:
https://lnkd.in/gYnTAgDh
This program is a collaborative effort between incubators and accelerators who are partnered with them through their Division of Research, Innovation & Ventures (DRIVe).
[post_title] => Bench to BARDA Start Up Series (Virtual)
[post_excerpt] => A virtual series providing insight into how innovators can take their solution from the benchtop to the Biomedical Advanced Research & Development Authority (BARDA).
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bench-to-barda-start-up-series-virtual
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-12 15:45:01
[post_modified_gmt] => 2022-09-12 15:45:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3908
[menu_order] => 24
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 1246
[post_author] => 3
[post_date] => 2014-08-12 17:20:57
[post_date_gmt] => 2014-08-12 17:20:57
[post_content] => Proskauer recently released a comprehensive U.S. IPO Analysis. The study examines key factors and aspects of the U.S. IPO market and provides market participants with extensive data about deal structures and terms, SEC comments and timing, financial profiles and accounting disclosures, corporate governance, and expenses. It also includes separate industry sections on health care, TMT, consumer/retail, financial services and industrials. Read the full study here: http://www.proskauer.com/files/uploads/Documents/Proskauer-2014-IPO_Study.pdf
[post_title] => Proskauer Releases 2014 IPO Study
[post_excerpt] => Proskauer recently released a comprehensive U.S. IPO Analysis.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => proskauer-releases-2014-ipo-study
[to_ping] =>
[pinged] =>
[post_modified] => 2015-01-28 17:03:47
[post_modified_gmt] => 2015-01-28 17:03:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1246
[menu_order] => 223
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 261
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)